Company: STAA
Filing Date: 2025-12-10
Form Type: DEFA14A
Source: 0001193125-25-313008
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-12-10
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material under §240.14a-12 |

STAAR SURGICAL COMPANY (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11                                                           |

On December 9, 2025, the Chief Executive Officer of STAAR Surgical Company (“STAAR” or the “Company”) sent the following email to STAAR employees:

Update on Alcon Merger

To: All Employees of STAAR

Dear Team,

I’m writing to provide an update regarding our proposed merger with Alcon.

Earlier today, STAAR and Alcon announced an amendment to the previously announced merger agreement. Alcon has agreed to a price “bump”, and the
amendment to the merger agreement increases the aggregate consideration paid for each share of STAAR common stock to $30.75/share, an increase of $2.75/share from the prior merger agreement. This is another clear sign that Alcon believes
strongly in STAAR, its employees and our bright future. The $30.75 price represents a ~66% premium to the closing price of STAAR common stock on August 4, 2025 and ~10% premium to $28/share. Alcon’s offer remains 100% cash.

As you may know, the Alcon merger transaction is contested, and shareholders had expressed objections to the $28/share merger price and other terms and
conditions of the merger. The amendment increases the merger price, and is intended to address